Abraham Ceesay
CIK 1722140 · Chief Executive Officer · last filed 2026-07-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$26.74M
Companies
6
Total Filings
36
Lifetime Open-Market Net
-$7.47M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RAPP | Chief Executive Officer | 621,546 | $41.73 | $25.94M | -$4.15M | 11 | 2026-07-15 |
| CRL | Director | 2,384 | $236.32 | $563.4K | $0 | 2 | 2026-05-11 |
| PCRX | Director | 9,039 | $26.16 | $236.4K | -$64.0K | 4 | 2025-09-08 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | President | 19,210 | $44.96 | $863.7K | -$3.26M | 6 | 2023-02-08 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | President | — | $18.07 | — | $0 | 1 | 2021-06-03 |
| scPharmaceuticals Inc. (SCPH) Delisted | Chief Operating Officer | — | $5.67 | — | $0 | 1 | 2018-01-19 |
Recent Filings · Page 3 of 4
36 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-04 | RAPP | Grant (A) | — | $0 | EDGAR |
| 2024-06-13 | PCRX | Grant (A) | +5,230 | $0 | EDGAR |
| 2024-06-10 | RAPP | Grant (A) | — | $0 | EDGAR |
| 2023-10-11 | PCRX | Grant (A) | — | $0 | EDGAR |
| 2023-05-08 | — | Notice (144/A) | −35,219 | -$1.13M | EDGAR |
| 2023-05-08 | — | Notice (144) | −35,219 | -$1.13M | EDGAR |
| 2023-05-05 | — | Notice (144) | −35,220 | -$1.11M | EDGAR |
| 2023-05-04 | — | Notice (144) | −35,220 | -$1.12M | EDGAR |
| 2023-02-08 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-09-12 | Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Mixed | — | -$371.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.